05.23.18

Wize Pharma Announces Presentation of New Data on LO2A in the Treatment of Dry Eye Syndrome in Patients with Sjögren’s Syndrome

Source: Wize Pharma

Wize Pharma announced recently reported new data on a formula known as LO2A, a product that Wize has in-licensed certain rights to purchase, market, sell and distribute.

The poster presentation presented at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting on May 2, 2018 in Honolulu, Hawaii, titled, “The anti-inflammatory effect of isotonic glycerol in Sjögren’s syndrome-related dry eye” was delivered by Dr. Huba J. Kiss and presented findings from a study conducted by him at the Department of Ophthalmology, Semmelweis University, in Budapest, Hungary.

“Based on this study, data shows that using LO2A resulted in a significant improvement of the subjective and objective symptoms of the Sjögren’s syndrome-related dry eye disease. This data supports our development efforts for LO2A in multiple markets including Israel where we are currently enrolling patients in a randomized, double-masked Phase IV study in this indication.  LO2A is already approved in the Netherlands for this indication,” Wize’s Chairman, Ron Mayron, said in a company news release.

LO2A resulted in a significant improvement of the subjective and objective symptoms of Sjögren’s syndrome-related dry eye disease in this study and importantly LO2A did so without the need for anti-inflammatory agents. Based on in vitro experiments, isotonic glycerol-induced decrease of HLA-DR expression may be responsible for this favorable effect.

The data showed that a 3-month long use of LO2A resulted in a decrease of the lid parallel conjunctival folds (LIPCOF) degree from the initial 2.48±0.75 on the right eye and 2.57±0.75 on the left eye to 1.33±0.73 and 1.38±0.67, respectively. P values for both the right and left eye were <0.001. Initial lissamine green staining of the eye surface also decreased significantly, with a P value of 0.001 for both the right and left eye from 1.76±0.89 and 1.95±0.86 to 0.29±0.56 and 0.29±0.56, respectively. There was a significant decrease, with a P value of <0.001, in the ocular surface disease index (OSDI) values from 55.81±15.19 to 32.54±19.51. Tear secretion did not change significantly, with a P value of 0.38 for the right eye and a P value of 0.45 for the left. 21 patients were enrolled in this prospective, unmasked, self-controlled study.

Related Content